High-flow Nasal Cannula Market Size Report, Share, Industry Analysis, Growth, 2034

High Flow Nasal Cannula Industry Prospective:

The global high flow nasal cannula market size was worth around USD 7.2 billion in 2024 and is predicted to grow to around USD 19.8 billion by 2034 with a compound annual growth rate (CAGR) of roughly 10.5% between 2025 and 2034.

Request Free Sample

High Flow Nasal Cannula Market: Overview

With up to 60 liters of warm, humidified oxygen delivered per minute, a high flow nasal cannula (HFNC) is a non-invasive respiratory support device, unlike traditional nasal cannulas.

Eliminating carbon dioxide and maybe generating a positive pressure effect can help reduce the effort needed for breathing by increasing the flow rate. The market for high-flow nasal cannulas (HFNCs) is rapidly growing due to their increasing use in the treatment of respiratory conditions across various healthcare environments.

Key Insights

• As per the analysis shared by our research analyst, the global high flow nasal cannula market is estimated to grow annually at a CAGR of around 10.5% over the forecast period (2025-2034).
• In terms of revenue, the global high flow nasal cannula market size was valued at around USD 7.2 billion in 2024 and is projected to reach USD 19.8 billion by 2034. 
• The increasing prevalence of COPD is expected to drive the high flow nasal cannula market over the forecast period.
• Based on the product type, the active humidifier segment is expected to hold the largest market share over the forecast period.
• Based on the application, the acute respiratory failure segment is expected to dominate the market expansion over the projected period.
• Based on the end-user, the hospitals and clinics segment is expected to dominate the market expansion over the projected period.
• Based on region, North America is expected to dominate the market during the forecast period.

High Flow Nasal Cannula Market: Growth Drivers

The increasing prevalence of respiratory disease drives market growth

The rising incidence of respiratory diseases is driving the expansion of the High-Flow Nasal Cannulas (HFNCs) market. Globally, this inclination is increasing demand for innovative, non-invasive oxygen delivery technologies, such as HFNC.

Particularly among older people and in areas with high degrees of tobacco use or air pollution, asthma, pneumonia, Chronic Obstructive Pulmonary Disease (COPD), and other respiratory disorders are on the increase. Particularly low- and middle-income countries find that the WHO ranks respiratory diseases third among all causes of death worldwide.

High Flow Nasal Cannula Market: Restraints

High cost of equipment and setup hinders market growth

Particularly in low- and middle-income nations, one of the main obstacles to the general acceptance of High Flow Nasal Cannula (HFNC) systems is the high equipment and setup costs.

High-performance flow generators, heated humidifiers, wide-bore nasal interfaces, and specialized circuits and filters are just a few of the elements HFNC systems demand. These components taken together make HFNC far more costly than conventional oxygen therapy approaches.

Furthermore, consumables such as sterile water, single-use cannulas, and humidification chambers are routinely replenished. Frequent maintenance, filter replacement, and technical support—all of which HFNC systems also demand—raise lifecycle costs.

Moreover, in certain healthcare systems, the government or insurance companies do not fully reimburse HFNC. Considering unknown financial returns, especially in private or mixed healthcare models, hospitals could be reluctant to use HFNC. All these factors are likely to hamper the expansion of the high flow nasal cannula industry.

High Flow Nasal Cannula Market: Opportunities

Rising collaboration offers a lucrative opportunity for market growth

The increased partnership is probably going to present a lucrative opportunity for the high flow nasal cannula market development over the projection term. For instance, according to a statement released by Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries LTD., the Desert Oasis Healthcare (DOHC) system in California began a respiratory patient monitoring program based on data from Teva's Digihaler System in March 2023.

Working with Rimidi, a top clinical management system focused on enhancing patient experiences, simplifying clinical processes, and fulfilling quality criteria, the program was designed. The first and only intelligent inhaler device available, which provides objective data to patients and doctors to enable better asthma management, is Teva's Digihaler.

High Flow Nasal Cannula Market: Challenges

The lack of skilled healthcare professionals poses a major challenge to market expansion

Particularly in underdeveloped nations, the High Flow Nasal Cannula (HFNC) sector suffers a major obstacle from the scarcity of qualified healthcare professionals. Because HFNC systems depend on experienced individuals to operate, monitor, and maintain them, their value in low-resource healthcare environments is limited. Up to 60 L/min, HFNC devices enable exact flow rate modifications; they also enable control of FiO2 levels and management of humidity and temperature.

Especially in acute respiratory failure, improper use might lead to insufficient therapy or patient harm. Moreover, several nations lack specialized respiratory therapists entirely. Nurses and general practitioners in low- and middle-income nations sometimes lack formal training in HFNC treatment. 

Request Free Sample

High Flow Nasal Cannula Market: Report Scope

High Flow Nasal Cannula Market: Segmentation

The global high flow nasal cannula industry is segmented based on product type, application, end-user, and region.

Based on the product type, the global high flow nasal cannula market is bifurcated into single heated tube, nasal cannula, active humidifier, and air blender. The active humidifier segment is expected to hold the largest market share over the forecast period. The demand for improved patient comfort, clinical effectiveness, and increased acceptance of HFNC therapy in intensive care and emergency settings is driving sector expansion.

Furthermore, technical developments are a major component driving segment growth. New active humidifiers have auto-adjusting humidity and temperature, compact and integrated designs, low maintenance, and improved infection control. These advances are propelling hospital improvements and replacements, hence boosting revenue growth.

Based on the application, the global high flow nasal cannula industry is bifurcated into acute respiratory failure, chronic obstructive pulmonary disease, acute heart failure, and others.

The acute respiratory failure segment is expected to dominate the market over the projected period. Acute Respiratory Failure (ARF) is a life-threatening condition in which the lungs are unable to supply adequate oxygen to the blood or effectively remove carbon dioxide. It is common in people with pneumonia, COPD exacerbations, acute respiratory distress syndrome (ARDS), and other conditions.

For instance, as per the data published by the World Health Organization, chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death worldwide.

Based on the end-user, the global market is bifurcated into hospitals and clinics, ambulatory care centers, long-term care centers, and others. The hospitals and clinics segment captures the prominent market share over the projected period. This is driven by their high patient volumes, demand for advanced respiratory support, and adherence to evolving clinical guidelines for non-invasive oxygen therapy.

High Flow Nasal Cannula Market: Regional Analysis

North America dominates the market over the projected period

North America is expected to dominate the global high flow nasal cannula market. This can be related to the rising prevalence of respiratory disorders such as COPD and asthma, which account for over 80% of healthcare spending due to their chronic nature.

Furthermore, the presence of both local and foreign producers in the region has increased the availability of nasal cannula goods at reasonable rates, propelling market expansion.

Besides, the Asia Pacific is expected to grow at the highest CAGR during the forecast period. This development can be attributed to a number of factors, including a large population, rising healthcare costs, and increased knowledge of respiratory illnesses.

Furthermore, the region's improving healthcare infrastructure, increased access to medical services, and rising demand for home healthcare solutions are propelling the market forward. The nasal cannula market in China presents great growth opportunities due to the country's huge population and high prevalence of chronic respiratory disorders caused by air pollution and other diseases.

High Flow Nasal Cannula Market: Competitive Analysis

The global high flow nasal cannula market is dominated by players like:

• Vapotherm Inc.
• Armstrong Medical Ltd
• Teleflex Inc.
• Salter Labs Inc.
• ResMed Inc.
• Becton Dickinson and Company
• TNI Medical AG
• Smiths Medical
• Hamilton Medical AG
• Flexicare Medical Ltd
• Fisher & Paykel Healthcare Limited
• Teijin Pharma Limited

The global high flow nasal cannula market is segmented as follows:

By Product Type

• Single Heated Tube
• Nasal Cannula
• Active Humidifier
• Air Blender

By Application

• Acute Respiratory Failure
• Chronic Obstructive Pulmonary Disease
• Acute Heart Failure
• Others

By End-user

• Hospitals and Clinics
• Ambulatory Care Centers
• Long-term Care Centers
• Others

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France 
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa